33 research outputs found
Factors of Affecting Sleep Quality in Cancer Patients
Aim:Sleep disorders are one of the most common problems in patients with malignancy and they severely decrease the quality of life. We sought to investigate the frequency of sleep disturbances, its quantity, quality and possible correlation with related factors such as depression and anxiety.Materials and Methods:150 patients participated and the Pittsburgh Sleep Quality Index was used to evaluate the sleep quality. It is a self-administered questionnaire and standardized measure of sleep quality. Total score of ≥5 shows that the quality of sleep is remarkably bad. Also a self-report measure of depression, the Beck Depression Inventory (BDI); and a self-report measure of anxiety, Beck Anxiety Inventory (BAI) were used.Results:Of the 150 patients, 74.0% has bad sleep quality (score >5 ). Mean PSQI total score was 7.34 (min 0-max 20). No differences were found between PSQI mean scores in terms of gender, radiotherapy (RT), chemotherapy (CHT), having chronic disease or having metastatic disease. NSAIDs and opioids were significantly correlated with PSQI (p<0.001). PSQI total scores are strongly associated with the BDI score (r=.424, p<0.001) and BAI score (r=.417, p<0.001).Conclusion:We found a high prevalence rate of bad sleep quality at 74%. Effective sleep treatment and psychological support should be provided in oncology clinics
Letter to the Editor: Total parenteral nutrition-induced Wernicke’s encephalopathy after oncologic gastrointestinal surgery
Prognostic Factors and Tumor Infiltrating Lymphocytes in Triple Negative Breast Cancer
Objective: Triple-negative-breast-cancer (TNBC) is a very heterogenous disease some of which are very aggressive and have poor prognosis. No targeted therapy is available. Immune response and tumor-infiltrating lymphocytes (TIL) can be related to longer disease-free survival (DFS) and overall survival (OS) in TNBC. Family history of cancer can be related poor prognosis, irrespective of genetic mutation
Induction Chemotherapy Increases the Survival of Patients with Primary Neuroectodermal Tumors of the Thorax
Prognostic value of aldehyde dehydrogenase 1 (ALDH1) in invasive breast carcinomas
Aldehyde dehydrogenase 1 (ALDH1) has been identified as a marker of cancer stem cells in breast cancer (BC). Recent studies showed that ALDH1 expression is correlated with poor prognostic parameters and worse clinical outcome in BC. We evaluated ALDH1 expression by immunohistochemistry in a series of 217 invasive BCs and investigated the correlation between ALDH1 expression and clinicopathological parameters, molecular subtypes (luminal A, luminal B, human epidermal growth factor receptor 2 [HER2] type, and triple-negative BC [TNBC]), and patient survival. There was a significant association between ALDH1 expression and tumor grade (p < 0.001), i.e., the expression of ALDH1 was higher in high-grade tumors. ALDH1 expression was significantly associated with estrogen and progesterone receptor (ER and PR) negativity (p < 0.001) and HER2 positivity (p = 0.001). ALDH1 expression ratios were higher in HER2 type and TNBC. There was a statistically significant correlation between ALDH1 negativity and luminal A subtype (p < 0.001). The overall and disease free survival were shorter in ALDH1+ tumors, although without statistical significance. We confirm that ALDH1 is a potentially important, poor prognostic factor in BC, associated with high histological grade, ER/PR negativity and HER2 positivity. For more accurate results, ALDH1 expression should be evaluated in larger case series including various types/subtypes of BC
Assocation between serum vascular endothelial growth factor, nitric oxide and urokinase-type plasminogen activator concentrations in patients with breast cancer
Is There Any Effect of Tumor Burden on Hemostatic Parameters in Cancer Patients? A Case Control Study of Hemostatic Abnormalities and Anticardiolipin Antibodies in Solid Tumors. "
Is There Any Effect of Tumor Burden on Hemostatic Parameters in Cancer Patients? A Case–Control Study of Hemostatic Abnormalities and Anticardiolipin Antibodies in Solid Tumors
Surgical Management of Breast Cancer in Turkey: a 30-Year Single-Center Retrospective Study of 2531 Patients
Mastectomy and lumpectomy are well-established surgical methods for the surgical treatment of breast cancer. The comparison of these methods within the 30-year period in terms of clinicopathological characteristics, recurrence, and survival patterns is required in order to provide aid in clinical decision-making. A total of 2531 women who underwent mastectomy or lumpectomy between 1982 and 2012 for primary invasive breast tumors were compared. Starting from 2003, similar variables for patients with primary invasive breast tumors who underwent sentinel node biopsy (SNB) were presented. Mastectomy was performed in 1870 patients and lumpectomy in 661. The median follow-up was 38 months for all patients. The ratio of mastectomy was lower for the patients who underwent SNB. There was no significant difference in breast cancer-related survival or disease-free survival between lumpectomy and mastectomy even after adjusting for the clinicopathological variables. Lumpectomy and mastectomy demonstrate similar survival rates for patients with invasive breast carcinoma. Tumor grade, stage, hormone receptor status, lymphovascular invasion, and distant recurrence have an impact on breast cancer-related survival